The Prognostic and Predictive Impact of BRAF Mutations in Deficient Mismatch Repair/Microsatellite Instability-High Colorectal Cancer: Systematic Review/Meta-Analysis

References

• Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov). SEER*Stat Database: Incidence - SEER Research Data, 9 Registries, Nov 2020 Sub (1975-2018) - Linked To County Attributes - Time Dependent (1990-2018) Income/Rurality, 1969-2019 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2021, based on the November 2020 submission.
   Google Scholar
• Loughrey MB , WaringPM, TanAet al. Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer. Fam. Cancer6(3), 301–310 (2007).
   PubMed Web of Science ®Google Scholar
• Parsons MT , BuchananDD, ThompsonB, YoungJP, SpurdleAB. Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification. J. Med. Genet.49(3), 151–157 (2012).
   PubMed Web of Science ®Google Scholar
• Schrock AB , OuyangC, SandhuJet al. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Ann. Oncol.30(7), 1096–1103 (2019).
   PubMed Web of Science ®Google Scholar
• Margonis GA , BuettnerS, AndreatosNet al. Association of BRAF mutations with survival and recurrence in surgically treated patients with metastatic colorectal liver cancer. JAMA Surg.153(7), e180996 (2018).
   PubMed Web of Science ®Google Scholar
• Spring KJ , ZhaoZZ, KaramaticRet al. High prevalence of sessile serrated adenomas with BRAF mutations: a prospective study of patients undergoing colonoscopy. Gastroenterology131(5), 1400–1407 (2006).
   PubMed Web of Science ®Google Scholar
• Davies H , BignellGR, CoxCet al. Mutations of the BRAF gene in human cancer. Nature417(6892), 949–954 (2002).
   PubMed Web of Science ®Google Scholar
• Fransén K , KlintenäsM, OsterströmA, DimbergJ, MonsteinHJ, SöderkvistP. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis25(4), 527–533 (2004).
   PubMed Web of Science ®Google Scholar
• Tie J , GibbsP, LiptonLet al. Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation. Int. J. Cancer128(9), 2075–2084 (2011).
   PubMed Web of Science ®Google Scholar
• Ikoma T , ShimokawaM, KotakaMet al. Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan. BMC Cancer21(1), 518 (2021).
   PubMed Web of Science ®Google Scholar
• Molina-Cerrillo J , SanRomán M, PozasJet al. BRAF mutated colorectal cancer: new treatment approaches. Cancers (Basel)12(6), 1571 (2020).
   PubMed Web of Science ®Google Scholar
• Caputo F , SantiniC, BardasiCet al. BRAF-mutated colorectal cancer: clinical and molecular insights. Int. J. Mol. Sci.20(21), 5369 (2019).
   PubMed Web of Science ®Google Scholar
• Cremolini C , DiBartolomeo M, AmatuAet al. BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. Ann. Oncol.26(10), 2092–2097 (2015).
   PubMed Web of Science ®Google Scholar
• Eng C . BRAF mutation in colorectal cancer: an enigmatic target. J. Clin. Oncol.39(4), 259–261 (2021).
   PubMed Web of Science ®Google Scholar
• Gatalica Z , TorlakovicE. Pathology of the hereditary colorectal carcinoma. Fam. Cancer7(1), 15–26 (2008).
   PubMed Web of Science ®Google Scholar
• Jenkins MA , HayashiS, O'SheaAMet al. Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. Gastroenterology133(1), 48–56 (2007).
   PubMed Web of Science ®Google Scholar
• Zlobec I , BihlMP, SchwarbH, TerraccianoL, LugliA. Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis. Int. J. Cancer127(2), 367–380 (2010).
   PubMed Web of Science ®Google Scholar
• Blaker H , AlwersE, ArnoldAet al. The association between mutations in BRAF and colorectal cancer-specific survival depends on microsatellite status and tumor stage. Clin. Gastroenterol. Hepatol.17(3), 455–462.e456 (2019).
   PubMed Web of Science ®Google Scholar
• Murcia O , JuarezM, Rodriguez-SolerMet al. Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: prognostic implications and response to chemotherapy. PLoS One13(9), e0203051 (2018).
   PubMed Web of Science ®Google Scholar
• Seppala TT , BohmJP, FrimanMet al. Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer. Br. J. Cancer112(12), 1966–1975 (2015).
   PubMed Web of Science ®Google Scholar
• Tran B , KopetzS, TieJet al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer117(20), 4623–4632 (2011).
   PubMed Web of Science ®Google Scholar
• Andre T , ShiuKK, KimTWet al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N. Engl. J. Med.383(23), 2207–2218 (2020).
   PubMed Web of Science ®Google Scholar
• Kalady MF , DejuliusKL, SanchezJAet al. BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis. Dis. Colon Rectum55(2), 128–133 (2012).
   PubMed Web of Science ®Google Scholar
• Goldstein J , TranB, EnsorJet al. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). Ann. Oncol.25(5), 1032–1038 (2014).
   PubMed Web of Science ®Google Scholar
• Malesci A , BassoG, BianchiPet al. Molecular heterogeneity and prognostic implications of synchronous advanced colorectal neoplasia. Br. J. Cancer110(5), 1228–1235 (2014).
   PubMed Web of Science ®Google Scholar
• Cohen R , BuhardO, CerveraPet al. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency. Eur. J. Cancer86, 266–274 (2017).
   PubMed Web of Science ®Google Scholar
• Lochhead P , KuchibaA, ImamuraYet al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J. Natl Cancer Inst.105(15), 1151–1156 (2013).
   PubMedGoogle Scholar
• Phipps AI , BuchananDD, MakarKWet al. BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics. Cancer Epidemiol. Biomarkers Prev.21(10), 1792–1798 (2012).
   PubMed Web of Science ®Google Scholar
• Wangefjord S , SundstromM, ZendehrokhNet al. Sex differences in the prognostic significance of KRAS codons 12 and 13, and BRAF mutations in colorectal cancer: a cohort study. Biol. Sex Differ.4(1), 17 (2013).
   PubMedGoogle Scholar
• Venderbosch S , NagtegaalID, MaughanTSet al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin. Cancer Res.20(20), 5322–5330 (2014).
   PubMed Web of Science ®Google Scholar
• Cohen R , TaiebJ, FiskumJet al. Microsatellite instability in patients with stage III colon cancer receiving fluoropyrimidine with or without oxaliplatin: an ACCENT pooled analysis of 12 adjuvant trials. J. Clin. Oncol.39(6), 642–651 (2021).
   PubMed Web of Science ®Google Scholar
• Le DT , KimTW, Van CutsemEet al. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J. Clin. Oncol.38(1), 11–19 (2020).
   PubMed Web of Science ®Google Scholar
• Lenz H-J , LonardiS, ZagonelVet al. Nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite instability-high/DNA mismatch repair deficient metastatic colorectal cancer: clinical update. J. Clin. Oncol.38(Suppl. 4), 11 (2020).
   PubMed Web of Science ®Google Scholar
• Overman MJ , McDermottR, LeachJLet al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, Phase 2 study. Lancet Oncol.18(9), 1182–1191 (2017).
   PubMed Web of Science ®Google Scholar
• Seppala TT , BohmJP, FrimanMet al. Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer. Br. J. Cancer112(12), 1966–1975 (2015).
   PubMed Web of Science ®Google Scholar
• Murcia O , JuarezM, Rodriguez-SolerMet al. Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: prognostic implications and response to chemotherapy. PLoS One13(9), e0203051 (2018).
   PubMed Web of Science ®Google Scholar
• Knight DA , NgiowSF, LiMet al. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J. Clin. Invest.123(3), 1371–1381 (2013).
   PubMed Web of Science ®Google Scholar
• Frederick DT , PirisA, CogdillAPet al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin. Cancer Res.19(5), 1225–1231 (2013).
   PubMed Web of Science ®Google Scholar
• Koya RC , MokS, OtteNet al. BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res.72(16), 3928–3937 (2012).
   PubMed Web of Science ®Google Scholar
• Wilmott JS , LongGV, HowleJRet al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin. Cancer Res.18(5), 1386–1394 (2012).
   PubMed Web of Science ®Google Scholar
• Ho PC , MeethKM, TsuiYC, SrivastavaB, BosenbergMW, KaechSM. Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNgamma. Cancer Res.74(12), 3205–3217 (2014).
   PubMed Web of Science ®Google Scholar
• Cooper ZA , JunejaVR, SagePTet al. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol. Res.2(7), 643–654 (2014).
   PubMed Web of Science ®Google Scholar
• Ilieva KM , CorreaI, JosephsDHet al. Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma. Mol. Cancer Ther.13(12), 2769–2783 (2014).
   PubMed Web of Science ®Google Scholar
• Cooper ZA , ReubenA, Austin-BrenemanJ, WargoJA. Does it MEK a difference? Understanding immune effects of targeted therapy. Clin. Cancer Res.21(14), 3102–3104 (2015).
   PubMed Web of Science ®Google Scholar
• Hugo W , ShiH, SunLet al. Non-genomic and immune evolution of melanoma acquiring MAPKi resistance. Cell162(6), 1271–1285 (2015).
   PubMed Web of Science ®Google Scholar
• Song C , PivaM, SunLet al. Recurrent tumor cell-intrinsic and -extrinsic alterations during MAPKi-induced melanoma regression and early adaptation. Cancer Discov.7(11), 1248–1265 (2017).
   PubMed Web of Science ®Google Scholar
• Hugo W , ShiH, SunLet al. Non-genomic and immune evolution of melanoma acquiring MAPKi resistance. Cell162(6), 1271–1285 (2015).
   PubMed Web of Science ®Google Scholar
• Hu-Lieskovan S , MokS, HometMoreno Bet al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci. Transl. Med.7(279), 279ra241 (2015).
   Web of Science ®Google Scholar
• Kopetz S , GrotheyA, YaegerRet al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N. Engl. J. Med.381(17), 1632–1643 (2019).
   PubMed Web of Science ®Google Scholar